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We previously demonstrated that the phytosphin-
gosine-induced apoptosis was accompanied by the con-
comitant induction of both the caspase-8-mediated and
mitochondrial activation-mediated apoptosis pathways.
In the present study, we investigated the role of mito-
gen-activated protein kinases (MAPKs) in the activation
of these two distinct cell death pathways induced by
phytosphingosine in human cancer cells. Phytosphin-
gosine caused strong induction of caspase-8 activity and
caspase-independent Bax translocation to the mito-
chondria. A rapid decrease of phosphorylated ERK1/2
and a marked increase of p38 MAPK phosphorylation
were observed within 10 min after phytosphingosine
treatment. Activation of ERK1/2 by pretreatment with
phorbol 12-myristate 13-acetate or forced expression of
ERK1/2 attenuated phytosphingosine-induced caspase-8
activation. However, Bax translocation and caspase-9
activation was unaffected, indicating that down-regula-
tion of the ERK activity is specifically required for the
phytosphingosine-induced caspase-8-dependent cell
death pathway. On the other hand, treatment with
SB203580, a p38 MAPK-specific inhibitor, or expression
of a dominant negative form of p38 MAPK suppressed
phytosphingosine-induced translocation of the pro-
apoptotic protein, Bax, from the cytosol to mitochon-
dria, cytochrome c release, and subsequent caspase-9
activation but did not affect caspase-8 activation, indi-
cating that activation of p38 MAPK is involved in the
mitochondrial activation-mediated cell death pathway.
Our results suggest that phytosphingosine can utilize
two different MAPK signaling pathways for amplifying
the apoptosis cascade, enhancing the understanding of
the molecular mechanisms utilized by naturally occur-
ring metabolites to regulate cell death. Molecular dis-
section of the signaling pathways that activate the ap-
optotic cell death machinery is critical for both our
understanding of cell death events and development of
cancer therapeutic agents.
Apoptosis can be induced via two distinct intracellular sig-
naling pathways, the death receptor-mediated or the mitochon-
drial activation-mediated pathway (1–3). The former pathway
is triggered by ligation of death receptors such as Fas and
TNFR.1 In this case, caspase-8 is recruited to the ligated re-
ceptors via FADD, an adaptor molecule, leading to its proteo-
lytic activation. The activated caspase-8 in turn cleaves and
activates caspase-3, which then initiates a set of events that
culminate in apoptosis (1, 2). In contrast to the death receptor
pathway, the mitochondrial pathway responds to anticancer
drugs and multiple classes of environmental stresses (3). These
stimuli cause redistribution of the proapoptotic Bcl-2 members,
such as Bax, from the cytosol to mitochondria. This event is
followed by reduction of the mitochondrial transmembrane po-
tential and the release of mitochondrial cytochrome c to the
cytosol. The released cytochrome c participates in the process
leading to caspase-9 activation, followed by activation of
caspase-3 (4). The mitochondrial activation-mediated pathway
has been shown to be required for Fas-induced apoptosis in
certain cell types that are classified as type II cells. In these
cells, Bid, a “BH3 only” protein of the Bcl-2 family, mediates
the release of cytochrome c from mitochondria initiated by
caspase-8 activation (5). Taken together, it appears that the
significance of each of the apoptotic pathways varies depending
on both stimulus and cell types.
The mitogen-activated protein kinases (MAPKs), a family of
serine/threonine kinases, are mediators of intracellular signals
in response to various stimuli. MAPKs include extracellular
signal-regulated kinase (ERK), c-Jun N-terminal protein ki-
nase (JNK), and p38 MAPK. The ERK pathway is activated by
mitogenic stimuli, such as growth factors, cytokines, and phor-
bol esters and plays a major role in regulating cell growth and
differentiation (6–9). The activation of the ERK pathway is
generally considered to be a survival signal induced by growth
factors against apoptotic signals (10, 11). It has recently been
reported that the ERK activation plays antiapoptotic roles in
Fas-, TRAIL-, chemotherapeutic drug- and serum deprivation-
induced apoptosis (12). Moreover, the MEK/ERK pathway
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blocks apoptosis by inhibiting the activation of caspase-8, a key
component of the death receptor pathway, induced by extrinsic
stimulation of Fas, TNFR, and TRAIL receptor (13, 14). In
contrast to ERKs, JNK and p38 MAPK are weakly activated by
growth factors but respond strongly to a variety of stress sig-
nals including tumor necrosis factor, interleukin-1, ionizing
and UV irradiation, hyperosmotic stress, and chemotherapeu-
tic drugs (15–19). Activation of these kinases has shown to
correlate well with the apoptosis induced by these stress stim-
uli. Additionally, studies using the inhibitors of JNK and p38
MAPK have suggested that JNK and/or p38 MAPK activation
is necessary for UV-, cytokine-, ceramide-, and chemotherapeu-
tic drug-induced apoptosis (20). However, the basis for cross-
talk between MAPKs and apoptotic cell death machinery re-
mains largely unclear.
Sphingolipid metabolites such as ceramides, sphingosines,
and sphingosine 1-phosphates have emerged as key regulators
of apoptosis (21). Ceramide is generated as a product of the
sphingomyelin hydrolysis, which is triggered by a variety of
apoptotic stimuli, including tumor necrosis factor-, anti-Fas,
and -radiation (22–27). Importantly, the apoptotic actions of
these stimuli are attenuated when the ceramide generation is
blocked. Moreover, direct exposure of cells to the cell-perme-
able ceramide analogs was shown to induce apoptosis, suggest-
ing that ceramide can act as a mediator of apoptosis. It has
been reported that ceramide induces apoptosis by the activa-
tion of the JNK signaling pathway (28). Ceramide can be fur-
ther metabolized by ceramidase to sphingosine, which can be
then phosphorylated by sphingosine kinase to form sphingo-
sine 1-phosphate (29). Whereas sphingosine induces apoptosis
in various cell types (30), sphingosine 1-phosphate antagonizes
the apoptotic actions of ceramide (30). Given the well estab-
lished role of these three sphingolipid metabolites in apoptosis,
other sphingolipid derivatives may also contribute to control-
ling apoptosis. Among these derivatives, phytosphingosine is
one of the most widely distributed natural sphingoid bases that
is abundant in fungi and plants and also found in animals
including humans. The structure of phytosphingosine is very
similar to sphingosine; phytosphingosine possesses a hydroxyl
group at C-4 of the sphingoid long-chain base, whereas sphin-
gosine has a trans double bond between C-4 and C-5. However,
the physiological role of phytosphingosine is largely unknown,
although it has recently been reported that phytosphingosine
exerts strong cytotoxic effects on Chinese hamster ovary cells
and modulates the muscarinic acetylcholine receptor-mediated
signal transduction pathway (31).
Previously, we have shown that phytosphingosine employs
two distinct apoptotic pathways, the caspase-8-dependent and
mitochondrial activation-dependent pathway, to induce apo-
ptosis in two different cell types, human T cell lymphoma,
Jurkat, and non-small cell lung cancer cell line, NCI-H460 (32).
This bifurcation of the signaling pathway induced by phyto-
sphingosine differs from those seen with other agents. Given
this unique feature of phytosphingosine, further analysis of its
action is expected to significantly advance understandings not
only of physiological functions of sphingolipid but also of the
apoptotic cell death control.
In this study, we investigate the mechanisms underlying the
simultaneous induction of both the caspase-8-mediated and
mitochondrial activation-mediated cell death by phytosphin-
gosine. The data suggest that down-regulation of the ERK
pathway is critical in the death receptor-independent activa-
tion of caspase-8, and activation of p38 MAPK is essential for
the induction of mitochondrial translocation of Bax and cyto-
chrome c release during phytosphingosine-induced apoptosis.
Since phytosphingosine appears to utilize two distinctive
MAPK signaling pathways for killing cells, understanding the
signaling mechanisms of phytosphingosine-induced cell death
may provide a better knowledge of the interrelationship be-
tween MAPKs and cell death machinery in mammalian
cell systems.
EXPERIMENTAL PROCEDURES
Cell Culture—Jurkat, human T cell lymphoma (Type II), and NCI-
H460 human non-small cell lung cancer cells were obtained from the
American Type Culture Collection (Manassas, VA). Cells were grown in
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS;
Invitrogen), penicillin, and streptomycin at 37 °C in a humidified incu-
bator with 5% CO2.
Plasmids—pCMV5-DN-p38 MAPK, an expression vector encoding
the dominant-negative mutant of p38 MAPK, and pLCEP4-DN-ERK,
the dominant negative mutants of ERK, were gifts of Dr. Roger Davis
(University of Massachusetts Medical School, Worcester, MA).
Materials—Phytosphingosine was purchased from Avanti (Alabaster,
AL). Polyclonal antibody to caspase-3 and monoclonal antibodies to
PARP and cytochrome c were obtained from Pharmingen (San Diego,
CA), and polyclonal antibodies to caspase-8 and -9, Bcl-2, Bax, Bid, and
HSP60 were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA). Polyclonal antibodies to phospho-p38 MAPK, caspase-3, and PARP
were obtained from Cell Signaling Technology (Beverly, MA). The p38
MAPK-specific inhibitor, SB203580, a broad spectrum caspase inhibi-
tor, Z-VAD-fmk, and the caspase-8 inhibitor, Z-IETD-fmk, were ob-
tained from Calbiochem.
Hoechst 33258 Staining—Hoechst 33258 staining was performed as
described previously (32). Briefly, cells were fixed with 4% paraformal-
dehyde for 30 min in room temperature and then washed once with
PBS. Hoechst 33258 (50 ng/ml) was added to the fixed cells, incubated
for 30 min at room temperature, and washed with PBS. Cells were
mounted and examined by fluorescence microscopy. Apoptotic cells
were identified by the condensation and fragmentation of their nuclei.
The percentage of apoptotic cells was calculated from the ratio of apo-
ptotic cells to total cells counted. At minimum, 500 cells were counted
for each treatment.
Flow Cytometric Analysis of Apoptosis—Apoptosis was identified and
quantified by flow cytometry with propidium iodide staining. Both
adherent and floating cells were collected after phytosphingosine treat-
ment, washed with ice-cold PBS, and fixed with 70% ice-cold ethanol
overnight at 4 °C. Fixed cells were washed twice with PBS and treated
with 1 mg/ml RNase for 30 min at 37 °C. Cellular DNA was stained with
50 ng/ml propidium iodide in PBS containing 0.05% Nonidet P-40. Cells
were then analyzed by a FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NJ). From the analysis of DNA histograms, the per-
centages of cells in different phases of cell cycle were evaluated. Cells
with DNA content less than the G1 phase (sub-G1) were taken as
apoptotic cells.
Extraction of DNA and Agarose Gel Electrophoresis—Cells were
treated with 5 or 10 g/ml phytosphingosine and were lysed in a lysis
buffer (20 mM Tris/HCl, pH 8.0, 0.1 mM EDTA, 1% SDS, and 0.5 mg/ml
proteinase K). DNA samples were extracted and separated by agarose
gel electrophoresis.
Western Blot Analysis—Western blot analysis was performed as de-
scribed (33). Briefly, cell lysates were prepared by extracting proteins
with lysis buffer (40 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.1% Nonidet
P-40) supplemented with protease inhibitors. Proteins were separated
by SDS-PAGE and transferred to nitrocellulose membrane. The mem-
brane was blocked with 5% nonfat dry milk in Tris-buffered saline and
then incubated with primary antibodies for 1 h at room temperature.
Blots were developed by peroxidase-conjugated secondary antibody and
proteins were visualized by ECL procedures (Amersham Biosciences)
according to the manufacturer’s recommendation.
Measurement of Mitochondrial Membrane Potential—Mitochondrial
membrane potential was determined as the retention of the mitochon-
dria-specific dye DiOC6(3) (Molecular Probes, Inc., Eugene, OR). Cells
were loaded with 30 nM DiOC6(3) during the last 30 min of phytosphin-
gosine treatment. After removal of the medium, the cells were washed
twice with PBS, and the relative amount of retained DiOC6(3) was
measured by flow cytometric analysis.
Preparation of Cytosolic and Mitochondrial Protein Fractions for the
Measurement of Cytochrome c and Bax Translocation—Cells were col-
lected and washed twice in ice-cold PBS, resuspended in S-100 buffer
(20 mM HEPES, pH 7.5, 10 mM KCl, 1.9 mM MgCl2, 1 mM EGTA, 1 mM
EDTA, mixture of protease inhibitors), and incubated on ice for 20 min.
After a 20-min incubation on ice, the cells were homogenized with a
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Dounce glass homogenizer and a loose pestle (Wheaton, Millville, NJ)
for 70 strokes. Cell homogenates were spun at 1,000  g to remove
unbroken cells, nuclei, and heavy membranes. The supernatant was
spun again at 14,000  g for 30 min to collect the mitochondria-rich
(pellet) and cytosolic (supernatant) fractions. The mitochondria-rich
fraction was washed once with the extraction buffer, followed by a final
resuspension in lysis buffer (150 mM NaCl, 50 mM Tris-Cl, pH 7.4, 1%
Nonidet P-40, 0.25% sodium deoxycholate, 1 mM EGTA) containing
protease inhibitors for Western blot analysis.
Immunofluorescence Analysis—For immunofluorescence analysis,
cells were fixed with 2% paraformaldheyde, permeabilized with 0.1%
Triton X-100 in PBS, and incubated with 25 nM Mitotracker Red
CMXRos (Molecular Probes) for 30 min at room temperature and then
washed three times with PBS. Cells were then incubated with rabbit
anti-human Bax diluted 1:200 in 5% FBS/PBS for 1 h at room temper-
ature in a humidified chamber. Excess antibody was removed by wash-
ing the coverslips three times with PBS. Cells were then incubated with
biotin-labeled goat anti-rabbit IgG (Zymed Laboratories Inc.) diluted
1:200 in 5% FBS/PBS, for 1 h protected from light at room temperature.
After washing three times with PBS, cells were incubated with fluores-
cein isothiocyanate-streptavidin diluted 1:200 in 5% FBS/PBS for 4 h.
After washing three times with PBS, coverslips were mounted onto
microscopic slides using ProLong antifade mounting reagent (Molecular
Probes). The slides were analyzed by a confocal laser-scanning micro-
scope (Leica Microsystems, Heidelberg, Germany).
Immune Complex Kinase Assay—ERK activity in phytosphingosine-
treated cell lysates was measured by the ability of these lysates to
phosphorylate PHAS-1 (Stratagene, La Jolla, CA), a substrate for ERK
(34). Briefly, cell lysates were prepared by extracting proteins with lysis
buffer (40 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.1% Nonidet P-40)
supplemented with protease inhibitors. Immunoprecipitation was per-
formed by incubating 200 g of lysate with anti-ERK-1 or ERK-2
antibody for 90 min and then adding 50 l of protein A-agarose (Sigma).
After a 90-min incubation at 4 °C, the immune complex was recovered
by centrifugation and washed three times with lysis buffer and then two
times with kinase reaction buffer (250 mM HEPES (pH 7.5), 10 mM
MgCl2, 200 M Na3VO4). The immune complex was resuspended in
kinase reaction buffer containing 120 g of PHAS-1 substrate along
with 2 Ci of [-32P]ATP (ICN). The reaction was allowed to proceed for
30 min at room temperature and was terminated by the addition of
SDS-loading buffer and boiling for 3 min. Phosphorylated PHAS was
resolved on 12.5% PAGE gels, dried, and autoradiographed.
RESULTS
Phytosphingosine Induces Death Receptor-independent
Caspase-8 Activation—We have previously shown that phyto-
sphingosine induces apoptosis in the human cancer cell line,
Jurkat. To confirm, we treated these cells with different doses
of phytosphingosine, and induction of apoptotic cell death was
analyzed. Fig. 1A shows that there is a dose- and time-depend-
ent increase of apoptotic cells after the phytosphingosine treat-
FIG. 1. Phytosphingosine induces the death receptor-independent caspase-8 activation and caspase-8-independent Bax translo-
cation in human cancer cells. A, Jurkat cells were treated with various concentrations of phytosphingosine for the time periods indicated. Cells
were stained with Hoechst 33258, and apoptotic cells were analyzed by fluorescence microscopy. Apoptotic cells containing condensed chromatin
fragments were scored and expressed as a percentage of the total cell number measured. Results from three independent experiments are shown
as means (bars, S.E.). B, total cell lysates were obtained from the cells incubated with 5 g/ml phytosphingosine or 50 ng of Ch11 for 3 h. Western
blot analysis was performed using anti-caspase-8, FADD, or -actin antibodies. Cell lysates were immunoprecipitated with anti-FADD antibody,
and immunocomplexes were separated by SDS-PAGE and probed with anti-caspase-8 antibody. The data represent a typical experiment conducted
three times with similar results. C, Jurkat cells were treated with 5 g/ml phytosphingosine for 3 h in the presence or absence of 30 M z-IETD-fmk.
Cell lysates were prepared, and Western blot analysis was performed for caspase-8, Bid, caspase-9, and -actin. Cytosolic fraction was prepared,
and cytochrome c was detected by Western blot analysis using anti-cytochrome c antibody. Mitochondrial fraction was analyzed for Bax protein
expression using anti-Bax antibody. The data represent a typical experiment conducted three times with similar results.
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ment, as measured by Hoechst 33258 staining for nuclei frag-
mentation and condensation. Several studies have suggested
that activation of caspase-8 depends upon its oligomerization,
which is mediated by the association of the DED domains of the
adaptor molecule, FADD, and caspase-8. This association re-
quires the interaction of FADD, either directly or indirectly
with surface receptors such as Fas or TNFR, which possess
death domains (1, 2). To determine whether death receptors
are involved in phytosphingosine-induced apoptosis, we per-
formed co-immunoprecipitation assays to analyze the associa-
tion of FADD and caspase-8 in Jurkat cells after treatment
with phytosphingosine. As shown in Fig. 1B, caspase-8 activa-
tion and interaction between FADD and caspase-8 were de-
tected in cells treated with Ch11, a soluble Fas ligand. In
contrast, caspase-8 was not found to be associated with FADD
upon phytosphingosine-mediated activation of caspase-8. This
suggests that caspase-8 activation triggered by phytosphin-
gosine occurs in a death receptor-independent fashion.
Phytosphingosine Induces Caspase-independent Bax Trans-
location, Cytochrome c Release, and Caspase-9 Activation in
Human Cancer Cells—We previously reported that treatment
of cells with phytosphingosine promoted cytochrome c release
and caspase-9 activation through acceleration of Bax translo-
cation to the mitochondria (32). To determine whether phyto-
sphingosine-induced Bax translocation is affected by the
caspase-8 activation, we examined the effect of Z-IETD-fmk, a
caspase-8-specific inhibitor, on the Bax translocation induced
by phytosphingosine. As shown in Fig. 1C, phytosphingosine
treatment dramatically redistributes Bax from the cytosol to
mitochondria, and the addition of Z-IETD-fmk failed to prevent
the intracellular redistribution of Bax. These results suggest
that Bax translocation, cytochrome c release, and caspase-9
activation occur in a caspase-8-independent fashion during the
apoptotic process triggered by phytosphingosine.
Phytosphingosine Suppresses the ERK Signaling Pathway—
MAPKs have been implicated in regulation of apoptosis in
response to various stimuli. To investigate a potential involve-
ment of ERKs in phytosphingosine-induced cell death, we first
examined their activities following phytosphingosine treat-
ment. ERK1/2 activities were determined by immunoblot anal-
ysis using anti-phospho-ERK1/2 antibody to detect the acti-
vated phosphorylated forms of ERK1/2 in Jurkat and NCI-
H460 cells. As shown in Fig. 2A, phytosphingosine treatment
led to a dramatic down-regulation of phosphorylated ERK1/2.
The phosphorylated ERK started to diminish within 2 min of
the phytosphingosine treatment (5 or 10 M, respectively, in
Jurkat and NCI-H460 cells). Suppression of ERK activity was
sustained for 3 or 6 h, respectively, in Jurkat and NCI-H460
cells, whereas the total expression level of ERK did not change
throughout the observed time course in these cells. This result
corroborates well with the results of ERK kinase assays, dem-
onstrating a marked decrease of ERK activity in these cells
after treatment with phytosphingosine (Fig. 2B).
Suppression of ERK Signaling Pathway Is Involved in the
Activation of Caspase-8 during Phytosphingosine-induced Apo-
ptosis—To determine whether suppression of ERK activity is
required for the phytosphingosine-induced apoptosis, we
treated cells with PMA, a very efficient ERK activator, and
analyzed its effect on phytosphingosine-induced apoptosis. As
expected, the decrease of phosphorylated ERK1/2 level was
inhibited by co-treatment of Jurkat cells with phytosphin-
gosine and PMA (Fig. 3A). Furthermore, PMA treatment mark-
edly suppressed the phytosphingosine-induced caspase-8 and
caspase-3 activation, PARP cleavage, and subsequent apopto-
sis (Fig. 3, A and B). However, cytochrome c release, caspase-9
activation, and Bax translocation triggered by phytosphin-
gosine were not affected by PMA treatment (Fig. 3A). To fur-
ther clarify the relationship between ERK activation and
phytosphingosine-induced cell death, we employed a specific
inhibitor of MEK, PD98059. A simultaneous treatment of cells
with PD98059, PMA, and phytosphingosine effectively re-
versed the inhibitory effect of PMA on phytosphingosine-in-
duced cell death (Fig. 4A). Furthermore, PD98059 treatment
effectively reversed the blockade of phytosphingosine-induced
caspase-8, caspase-3 activation, and PARP cleavage by PMA
(Fig. 4B). In fact, treating cells with PD98059 alone without
PMA potentiates the phytosphingosine-induced cell death (Fig.
4A), caspase activation, and PARP cleavage (Fig. 4B).
FIG. 2. Phytosphingosine inhibits the ERK1/2 activity in human cancer cells. A, Jurkat and NCI-H460 cells were treated with 5 or 10
g/ml phytosphingosine, respectively, for the time periods indicated. Cell lysates were subjected to Western blot analysis with anti-ERK1/2 or
phospho-ERK1/2 antibodies. The data represent a typical experiment conducted at least three times with similar results. B, Jurkat cells were
treated with 5 g/ml phytosphingosine for 3 h. Cell lysates were prepared, and an ERK kinase assay was performed after immunoprecipitation of
ERK using anti-ERK1 or ERK2 antibody. The kinase activity of the precipitates was measured with PHAS-1 as a substrate. The data represent
a typical experiment conducted at least three times with similar results.
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To further investigate the relationship between ERK activity
and caspase-8 activation, we examined effects of the ectopically
expressed ERK1 and ERK2 on biochemical features of the
phytosphingosine-induced apoptosis. As shown in Fig. 5A,
caspase-8 activation induced by phytosphingosine treatment
was significantly inhibited by overexpression of ERK1 or
ERK2, whereas it did not affect the phytosphingosine-induced
caspase-9 activation. Furthermore, ERK1 or ERK2 overexpres-
sion partially prevented the phytosphingosine-induced apo-
ptotic cell death (Fig. 5B). In addition, ectopic expression of
dominant negative forms of ERK1 or ERK2 significantly en-
hanced the phytosphingosine-induced cell death and caspase-8
activation and reversed the PMA-induced suppression of phyto-
sphingosine-mediated cell death and caspase-8 activation (Fig.
5C). Taken together, the caspase-8-dependent apoptotic proc-
ess induced by phytosphingosine requires suppression of the
MEK/ERK signaling pathway. However, this signaling path-
way does not seem to be critical in the mitochondria-mediated
apoptosis pathway.
Selective Activation of p38 MAPK during Phytosphingosine-
induced Apoptosis—To determine the role of p38 MAPK and
JNK in phytosphingosine-induced apoptosis, we first analyzed
the activation status of p38 MAPK and JNK by Western blot
analysis with antibodies specific to the phosphorylated form of
these two kinases. As shown in Fig. 6A, treatment with phyto-
sphingosine resulted in a dramatic increase of the phosphoryl-
FIG. 3. PMA blocks the activation of caspase-8 by phytosphingosine but did not affect phytosphingosine-induced caspase-9
activation. A, Jurkat cells were treated with 5 g/ml of phytosphingosine in the presence or absence of 100 nM PMA for 3 h. Cells were harvested,
lysed, and subjected to Western blot analysis using anti-phospho-ERK1/2, caspase-8, caspase-9, caspase-3, or PARP antibodies. Cytosolic fraction
was used for analysis of the cytochrome c expression, whereas Bax and HSP60 proteins were detected by Western blot analysis of the mitochondrial
fraction. The data represent a typical experiment conducted three times with similar results. B, Jurkat cells were stained with Hoechst 33258, and
apoptotic cells were quantitated by fluorescence microscopy. Apoptotic cells containing condensed chromatin fragments were scored and expressed
as a percentage of the total cell number counted. Results from three independent experiments are shown as means  S.E. The data represent a
typical experiment conducted three times with similar results.
FIG. 4. PD98059 attenuates the inhibitory effect of PMA in phytosphingosine-induced cell death. Jurkat cells were pretreated with 100
nM PMA and/or 30 M PD98059 for 30 min and then with 5 g/ml phytosphingosine for 3 h. A, cells were stained with Hoechst 33258, and apoptotic
cells were quantitated by fluorescence microscopy as described above. Results from three independent experiments are shown as means  S.E. B,
cell lysates were prepared, and Western blot analysis was performed using anti-caspase-8, caspase-3, or PARP antibodies. The data represent a
typical experiment conducted three times with similar results.
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ated form of p38 MAPK, indicating its activation in Jurkat as
well as NCI-H460 cells. p38 MAPK activation was apparent at
5 min, peaked at 1 h after phytosphingosine treatment, and
was sustained for 3 or 6 h, respectively in Jurkat and NCI-
H460 cells. In contrast, the level of the phosphorylated form of
JNK did not alter over the time course examined in both cell
lines. The total cellular level of p38 MAPK and JNK also
remained constant. These results suggest that phytosphin-
gosine can selectively induce activation of p38 MAPK during
the apoptotic process of human cancer cells.
Activation of p38 MAPK Is Independent of Caspase Activity—
It has been reported that p38 MAPK acts at a step prior to
caspase activation during the apoptotic process induced by
certain stimuli (35, 36). In disagreement with these reports,
activation of p38 MAPK has been observed to be dependent on
caspase activity under different experimental conditions (37).
To determine whether caspase activities are required for the
p38 MAPK activation in phytosphingosine-mediated apoptosis,
we examined the effect of a broad spectrum caspase inhibitor,
Z-VAD-fmk, on the p38 MAPK activation by phytosphingosine.
As shown in Fig. 6B, phytosphingosine-induced p38 MAPK
activation was not inhibited by Z-VAD-fmk. Additionally, Z-
DEVD-fmk, a caspase-3-specific inhibitor, also did not affect
the activation of p38 MAPK induced by phytosphingosine (data
FIG. 5. Overexpression of ERK1 or
ERK2 inhibits phytosphingosine-in-
duced caspase-8 activation and apo-
ptosis but not caspase-9 activation. A,
NCI-H460 cells were transfected with ei-
ther empty vector (PCEP4) or the expres-
sion vector for ERK1 or ERK2. These cells
were treated with 5 g/ml phytosphin-
gosine for 3 h. Cell lysates were prepared,
and Western blot analysis was performed
using anti-phospho-ERK1/2, caspase-8, or
caspase-9 antibodies. The data represent
a typical experiment conducted three
times with similar results. B, control and
ERK1 or ERK2-overexpressing cells were
treated with 5 g/ml phytosphingosine for
3 h. These cells were stained with Ho-
echst 33258 dye and analyzed as de-
scribed above (Fig. 3B). Results represent
averages of three independent experi-
ments  S.E. C, NCI-H460 cells overex-
pressing the dominant negative form of
ERK1 or ERK2 were treated with or with-
out 100 nM PMA for 30 min followed by 5
g/ml phytosphingosine for 3 h. After
staining with Hoechst 33258, apoptotic
cells were quantitated as described above.
Results represent averages of three inde-
pendent experiments  S.E. (upper
panel). Cell lysates were subjected to
Western blot analysis using anti-
caspase-8 antibody (bottom panel). The
data represent a typical experiment con-
ducted three times with similar results.
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not shown). However, both inhibitors completely blocked the
phytosphingosine-induced caspase activation and apoptotic cell
death (data not shown). These data strongly suggest that in-
duction of the p38 MAPK activity by phytosphingosine is inde-
pendent of caspase activation, and it is likely to be an upstream
event of caspase activation in phytosphingosine-induced apo-
ptotic cascade.
Interference with the p38 MAPK Pathway Prevents Induction
of Mitochondria-mediated Apoptosis by Phytosphingosine—Us-
ing a p38 MAPK inhibitor, SB203580, we investigated effects of
the p38 MAPK inhibition on apoptotic cell death induced by
phytosphingosine. As shown in Fig. 7A, SB203580, at a concen-
tration sufficient to completely inhibit p38 MAPK activity,
inhibited two representative aspects of apoptosis (38), namely
loss of mitochondrial transmembrane potential and increase in
the plasma membrane permeabilization. Moreover, preincuba-
tion with SB203580 markedly inhibited DNA fragmentation
and apoptotic cell death induced by phytosphingosine (Fig. 7,
B and C). These data indicate that p38 MAPK is involved
in the mitochondria-mediated apoptotic process induced by
phytosphingosine.
Activation of p38 MAPK Is Required for Phytosphingosine-
mediated Release of Cytochrome c and Intracellular Redistri-
bution of the Cell Death Activator, Bax—We next investigated
effects of inhibition of the p38 MAPK pathway on the caspase
activation induced by phytosphingosine. As shown in Fig. 8, A
and B, treatment with SB203580 or forced expression of a
dominant negative form of p38 MAPK did not alter the
caspase-8 cleavage induced by phytosphingosine. However, the
phytosphingosine-induced caspase-9 activation was completely
blocked by SB203580 treatment or by overexpression of a dom-
inant negative p38 MAPK. These results suggest that activa-
tion of p38 MAPK is required for the caspase-9 but not for the
caspase-8 activation during phytosphingosine-induced apopto-
sis. Furthermore, p38 MAPK may regulate some aspects of
mitochondrial function, such as cytochrome c release in re-
sponse to phytosphingosine, as proposed by other studies using
different experimental systems (39, 40). Therefore, we investi-
gated the role of p38 MAPK in cytochrome c release from
mitochondria induced by phytosphingosine treatment. As pre-
dicted, SB203580 treatment or overexpression of dominant
negative p38 MAPK effectively blocked the phytosphingosine-
induced cytochrome c release (Fig. 8, A and B). These results
indicate that p38 MAPK acts as an important mediator of the
phytosphingosine-induced cytochrome c release from mitochon-
dria, independent of caspase-8 activation.
We next studied whether p38 activation is required for the
mitochondrial translocation of Bax proteins after phytosphin-
gosine treatment. The intracellular redistribution of Bax pro-
teins was evaluated by immunoblot analysis of mitochondrial
fractions and by confocal laser-scanning microscopy. Phyto-
sphingosine treatment (5 M) induced significant changes in
distribution of Bax proteins (Fig. 8). In contrast, inhibition of
the p38 MAPK pathway by SB203580 or by ectopic expression
of a dominant negative p38 MAPK dramatically suppressed the
phytosphingosine-induced mitochondrial translocation of Bax
proteins in Jurkat cells (Fig. 8, A and B). In agreement with
these data, SB203580 effectively blocked the phytosphin-
FIG. 6. Phytosphingosine induces caspase-independent activation of p38 MAPK in Jurkat or NCI-H460 cells. A, Jurkat and
NCI-H460 cells were treated with 5 or 10 g/ml of phytosphingosine for the time periods indicated. Cell lysates were prepared, and Western blot
analysis was performed using anti-p38 MAPK, phospho-p38 MAPK, JNK, or phospho-JNK antibodies. The data represent a typical experiment
conducted at least three times with similar results. B, Jurkat cells were treated with 5 g/ml phytosphingosine for the time indicated in the
presence or absence of 30 M z-VAD-fmk. Expression of p38 MAPK and phosphorylated p38 MAPK was analyzed by Western blot analysis. The
data represent a typical experiment conducted three times with similar results.
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gosine-induced Bax translocation to mitochondria observed by
confocal laser-scanning microscopy (Fig. 8C). Interestingly,
PD98059, a MEK inhibitor, which enhanced phytosphingosine-
induced apoptotic cell death, did not affect the intracellular
redistribution of Bax proteins (data not shown). Taken to-
gether, these results suggest that activation of the p38 MAPK
signaling pathway is critical in regulating translocation of Bax
proteins from the cytosol to mitochondria during phytosphin-
gosine-induced apoptosis.
DISCUSSION
The functional mechanism of anticancer activity of ceramide
or sphingosine has been studied extensively. Despite the struc-
tural similarity to ceramide and sphingosine, however, physi-
ological roles of phytosphingosine are still largely unknown.
Moreover, the functional mechanism by which phytosphin-
gosine induces apoptotic cell death is unclear. In this study, we
found that phytosphingosine treatment resulted in a marked
attenuation of ERK activity and a rapid activation of p38
MAPK. We also demonstrated that suppression of the ERK
pathway is a critical step in death receptor-independent acti-
vation of caspase-8, and p38 MAPK activation is required for
mitochondrial translocation of Bax during the phytosphin-
gosine-induced apoptotic process.
It has been known that the ERKs are activated in response to
various growth factor stimulations, whereas the JNK and p38
MAP kinase are activated by various forms of stress signals
(41). These studies support the general view that activation of
the ERK pathway delivers a survival signal that counteracts
proapoptotic effects associated with JNK and p38 MAPK acti-
vation (42–47). The prosurvival function of ERK was demon-
strated again in a recent report that showed that inhibition of
ERK signaling leads to an increased sensitivity to cisplatin in
ovarian cancer cells (48). In addition, activation of the MEK/
ERK signaling pathway in activated Jurkat cells has been
shown to suppress TRAIL-mediated apoptosis in a similar fash-
ion as it suppresses Fas-mediated apoptosis (13).
It is now well established that an exogenous treatment of
sphingosine causes apoptosis in a variety of leukemic or solid
tumor cell lines, and a large body of knowledge has been accu-
mulated regarding the role of MAPKs in sphingosine-induced
apoptosis. For instance, sphingosine treatment results in a
complete inhibition of ERK activity in leukemic and solid can-
cer cells (49–51), indicating that inhibition of the ERK path-
way may be required for sphingosine-induced apoptosis. In
contrast to sphingosine or ceramide, sphingosine 1-phosphate
promotes cell survival in response to various apoptotic stimuli
FIG. 7. Inhibition of p38 MAPK suppresses phytosphingosine-induced loss of mitochondria transmembrane potential and apo-
ptosis in Jurkat cells. A, Jurkat cells were treated with 5 g/ml of phytosphingosine for 3 h in the presence or absence of 30 M SB203580.
Mitochondrial transmembrane potential of these cells was determined by retention of DiOC6(3) added during the last 30 min of phytosphingosine
treatment. After removal of the medium, propidium iodide (PI) was added, and the amount of retained DiOC6(3) and propidium iodide uptake were
measured by flow cytometry. B, cells were stained with Hoechst 33258, and apoptotic cells were quantitated as described above. Results from three
independent experiments are shown as means  S.E. C, Jurkat cells were treated with 5 g/ml phytosphingosine for 3 h in the presence or absence
of 30 M SB203580. Total DNAs were extracted from the cells and subjected to agarose gel electrophoresis, stained with ethidium bromide, and
visualized under UV light.
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such as tumor necrosis factor-, Fas ligation, serum depriva-
tion, ionizing radiation, anticancer drugs, or ceramide (30, 52–
61). The protective effect of sphingosine 1-phosphate from cell
death stimuli is accomplished through the activation of the
ERK pathway (23, 62). In the present study, we provide evi-
dence that inhibition of the MEK/ERK signaling pathway is
important for induction of apoptotic cell death by phytosphin-
gosine in Jurkat and NCI-H460 cells. We demonstrate that
inhibition of the MEK/ERK signaling pathway is required for
the phytosphingosine-induced caspase-8 activation. A rapid de-
crease of phosphorylated-ERK1/2 is observed within 10 min
after treatment with phytosphingosine. Pretreatment with
PMA or overexpression of ERK1/2 attenuates phytosphin-
gosine-induced caspase-8 activation and apoptotic cell death
but does not affect Bax translocation or caspase-9 activation,
indicating that suppression of ERK activity during phytosphin-
gosine-induced apoptosis is required only for the caspase-8
activation. We have previously reported that the phytosphin-
gosine-mediated caspase-8 activation and apoptosis were inde-
pendent of the death receptors and/or FADD (32). In this study,
we show that the adaptor molecule, FADD, and caspase-8 do
not interact during phytosphingosine-induced apoptosis. How-
ever, both, the precursor and activated forms of caspase-8
co-precipitate with FADD after treatment with soluble Fas
ligand. These results support the emerging hypothesis that
caspase-8 activation is not strictly dependent on death receptor
engagement. In death receptor-mediated apoptosis, caspase-8
activity is often responsible for the cleavage of a cytosolic sub-
strate (e.g. Bid), which then triggers the cytochrome c release
from mitochondria. In contrast, phytosphingosine induced cy-
FIG. 8. Inhibition of p38 MAPK blocks Bax translocation, cytochrome c release, and caspase-9 activation induced by phytosphin-
gosine treatment. A, Jurkat cells were treated with 5 g/ml of phytosphingosine for 3 h in the presence or absence of 30 M SB203580. Cell lysates
were subjected to Western blot analysis using anti-p38 MAPK, phosphorylated p38 MAPK, or caspase-8, -9, or -3 antibodies. Cytochrome c and Bax
expression were analyzed as described above (Fig. 3A). The data represent a typical experiment conducted three times with similar results. B,
Jurkat cells overexpressing a dominant negative form of p38 MAPK were treated with phytosphingosine (5 g/ml) for 3 h. Western blot analysis
of cell lysates was performed using anti-p38 MAPK, phospho-p38 MAPK, caspase-8, caspase-9, or caspase-3 antibodies. Cytochrome c and Bax were
detected as described above (Fig. 3A). The data represent a typical experiment conducted three times with similar results. C, cells were treated
with 5 g/ml phytosphingosine (PS) for 3 h in the presence or absence of 30 M SB203580 (SB). Cells were incubated with Mitotracker and stained
with fluorescein isothiocyanate-conjugated anti-Bax antibody and analyzed by confocal laser-scanning microscopy. Mitochondrial localization of
Bax was defined by yellow spots, indicating overlap of fluorescein isothiocyanate and Mitotracker.
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tochrome c release from mitochondria in Jurkat cells without
affecting Bid cleavage (32). These results suggest that two
separate pathways may be involved in phytosphingosine-in-
duced apoptosis; one is caspase-8-dependent, and the other is
mitochondria-controlled and caspase-8-independent.
The stress-activated protein kinases JNK and p38 MAPK
represent two independent parallel MAPK pathways that are
believed to play important roles in apoptosis (63). For instance,
sphingosine was reported to activate JNKs in HL-60 and U937
cells (49, 50). Because JNKs are activated by various stress
stimuli, including ceramide (27), sphingosine has been sug-
gested to be a key mediator of stress responses leading to
activation of JNKs. However, this activation of JNKs by sphin-
gosine did not modulate expression of c-Jun mRNA and protein
(49). In addition, inhibition of c-Jun activity by transfecting a
dominant negative form of c-Jun did not affect sphingosine-
induced cell death (29). These findings indicate that the activ-
ities of JNKs ultimately leading to modulation of AP-1 tran-
scription factor activity do not contribute to sphingosine-
mediated cell death. In agreement with these reports, our
results suggest that phytosphingosine does not affect the ex-
pression level of JNKs or their activity. It has been reported
that p38 MAPK is positively implicated in induction of apopto-
sis in response to various stimuli (25, 64, 66, 67). Consistent
with these findings, we also found that the p38 MAPK pathway
plays an important role in phytosphingosine-induced apoptotic
cell death. Inhibition of p38 MAPK by SB203580 or overexpres-
sion of dominant negative p38 MAPK attenuated apoptotic cell
death induced by phytosphingosine. The rapid phosphorylation
of p38 MAPK after phytosphingosine treatment suggests that
activation of p38 MAPK plays a key role in the early events of
pytosphingosine-induced apoptosis. This conclusion is further
supported by observations made in this study of the role of p38
MAPK in other apoptotic regulatory events, such as Bax trans-
location, loss of mitochondrial membrane potential, cytochrome
c release, and caspase activation after phytosphingosine treat-
ment. Based on our data, we suggest that p38 MAPK acts at an
early step prior to activation of the upstream caspase cascade,
resulting in activation of the effector caspase-3 as reported
previously (35, 36). Under certain circumstances, caspases may
regulate the activation of p38 MAPK, as in Fas-treated Jurkat
cells (37). However, our results demonstrate that the activation
of p38 MAPK by phytosphingosine is insensitive to the broad
spectrum caspase inhibitor, Z-VAD-fmk, or the caspase-3 spe-
cific inhibitor, Z-DEVD-fmk, suggesting that the activation of
p38 MAPK during phytosphingosine-induced apoptosis is ei-
ther upstream or independent of the caspase cascade. The
present study also suggests that Bax translocation to the mito-
chondria in response to phytosphingosine is subject to regulation
by p38 MAPK. We observed that the p38 MAPK-specific inhibi-
tor, SB203580, is very effective at inhibiting both p38 MAPK and
caspase-9 activation and protected cells from the phytosphin-
gosine-induced apoptotic cell death. We also showed that
SB203580 blocked translocation of the proapoptotic protein, Bax,
from the cytosol to mitochondria after phytosphingosine treat-
ment. Moreover, forced expression of a dominant negative form of
p38 MAPK completely blocked Bax translocation, cytochrome c
release, caspase-9 activation, and subsequent cell death induced
by phytosphingosine. Consistent with the results of other reports,
our data suggest that p38 MAPK is involved in induction of
apoptosis (25, 64, 66, 67) and that it acts at a step prior to
mitochondrial dysfunction and caspase activation (35, 36).
In summary, we report here that phytosphingosine concom-
itantly induces both the caspase-8-mediated and mitochondrial
activation-mediated cell death through differential regulation
of MAP kinase signaling pathways (Fig. 9). Suppression of ERK
signaling is required for activation of caspase-8 and subsequent
downstream caspase activation, whereas activation of p38
MAPK signaling is essential for Bax translocation to the mito-
chondria and subsequent mitochondria-mediated cell death
pathway during phytosphingosine-induced apoptotic cell
death. Interestingly, phytosphingosine appears to utilize two
distinct MAPK signaling pathways for amplifying the apopto-
sis cascade. Elucidating the molecular mechanisms utilized by
naturally occurring metabolites to regulate cell death is critical
for both our understanding of cell death events and the devel-
opment of cancer therapeutic agents.
FIG. 9. Schematic model of the roles
of MAPKs in phytosphingosine-in-
duced cell death. Phytosphingosine
suppresses ERK1/2 and activates p38
MAPK. Suppression of ERK1/2 induces
the activation of caspase-8, which leads to
caspase-3 activation resulting in apop-
totic cell death. Activation of p38 MAPK
induces translocation of Bax from the cy-
tosol to mitochondria, reducing mitochon-
drial membrane potential. This leads to
cytochrome c release, which results in
caspase-9 and -3 activation and, eventu-
ally, apoptotic cell death. Since phyto-
sphingosine appears to utilize two differ-
ent signaling pathways for killing cells,
understanding the signaling mechanisms
of phytosphingosine-induced cell death
may provide the basis for cross-talk
between MAPKs and the apoptotic
machinery.
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